BRPI0922730A2 - antibody formulation - Google Patents

antibody formulation

Info

Publication number
BRPI0922730A2
BRPI0922730A2 BRPI0922730-0A BRPI0922730A BRPI0922730A2 BR PI0922730 A2 BRPI0922730 A2 BR PI0922730A2 BR PI0922730 A BRPI0922730 A BR PI0922730A BR PI0922730 A2 BRPI0922730 A2 BR PI0922730A2
Authority
BR
Brazil
Prior art keywords
formulation
antibody
formulations
acz885
histidine
Prior art date
Application number
BRPI0922730-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Momm Joachim
Wallny Hans-Joachim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922730(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0922730A2 publication Critical patent/BRPI0922730A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0922730-0A 2008-12-10 2009-12-09 antibody formulation BRPI0922730A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170884.4 2008-12-10
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
PCT/EP2009/066675 WO2010066762A1 (en) 2008-12-10 2009-12-09 Antibody formulation

Publications (1)

Publication Number Publication Date
BRPI0922730A2 true BRPI0922730A2 (en) 2018-11-06

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922730-0A BRPI0922730A2 (en) 2008-12-10 2009-12-09 antibody formulation

Country Status (31)

Country Link
US (3) US20110236398A1 (https=)
EP (4) EP2196476A1 (https=)
JP (6) JP6143416B2 (https=)
KR (2) KR101762966B1 (https=)
CN (3) CN104399076B (https=)
AU (1) AU2009324371B2 (https=)
BR (1) BRPI0922730A2 (https=)
CA (1) CA2745938C (https=)
CL (1) CL2011001406A1 (https=)
CO (1) CO6361952A2 (https=)
CY (2) CY1117735T1 (https=)
DK (2) DK2376533T3 (https=)
EC (1) ECSP11011192A (https=)
ES (2) ES2900624T3 (https=)
HR (2) HRP20211899T1 (https=)
HU (2) HUE028408T2 (https=)
IL (3) IL264316B2 (https=)
LT (1) LT3072906T (https=)
MA (1) MA33023B1 (https=)
MX (1) MX2011006242A (https=)
MY (2) MY166050A (https=)
NZ (1) NZ592918A (https=)
PE (1) PE20120342A1 (https=)
PL (2) PL3072906T3 (https=)
PT (2) PT2376533T (https=)
RU (2) RU2745601C2 (https=)
SI (2) SI2376533T1 (https=)
SM (1) SMT201600222B (https=)
TN (1) TN2011000229A1 (https=)
WO (1) WO2010066762A1 (https=)
ZA (1) ZA201103362B (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120076779A1 (en) 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
EP3539374A1 (en) * 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
MA37946B1 (fr) * 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
TW201513882A (zh) 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
CA2959571A1 (en) * 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
LT3386541T (lt) 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
WO2018002031A1 (en) * 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
JP2019521161A (ja) * 2016-07-21 2019-07-25 ノバルティス アーゲー 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
CA3061874A1 (en) * 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN111315412A (zh) * 2017-09-13 2020-06-19 诺华股份有限公司 Il-1b结合抗体用于治疗酒精性肝炎的用途
WO2019180261A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
SG11202103670XA (en) * 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN120241997A (zh) * 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
EP4268803A4 (en) * 2020-12-22 2025-04-16 Bio-Thera Solutions, Ltd. Stable antibody preparation, preparation method for same, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
PL1940465T3 (pl) 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
SI2376533T1 (sl) 2016-07-29
DK2376533T3 (en) 2016-06-27
LT3072906T (lt) 2021-12-27
IL276622A (en) 2020-09-30
MY166050A (en) 2018-05-22
RU2563179C2 (ru) 2015-09-20
RU2015132431A3 (https=) 2018-12-24
JP2023109938A (ja) 2023-08-08
EP2376533A1 (en) 2011-10-19
IL212922B (en) 2019-02-28
MX2011006242A (es) 2011-06-24
HRP20160754T1 (hr) 2016-08-12
CN104399076A (zh) 2015-03-11
US8623367B2 (en) 2014-01-07
PL3072906T3 (pl) 2022-01-24
DK3072906T3 (da) 2021-12-13
IL264316A (en) 2019-02-28
ECSP11011192A (es) 2011-08-31
US20200384108A1 (en) 2020-12-10
HRP20211899T1 (hr) 2022-03-04
EP2196476A1 (en) 2010-06-16
IL264316B1 (en) 2023-09-01
ZA201103362B (en) 2012-01-25
EP2376533B1 (en) 2016-03-30
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
IL212922A0 (en) 2011-07-31
RU2015132431A (ru) 2018-12-24
RU2011127913A (ru) 2013-01-20
SMT201600222B (it) 2016-08-31
HUE028408T2 (en) 2016-12-28
RU2745601C2 (ru) 2021-03-29
JP2012511540A (ja) 2012-05-24
PT3072906T (pt) 2021-12-14
CY1117735T1 (el) 2017-05-17
JP7286595B2 (ja) 2023-06-05
SI3072906T1 (sl) 2022-01-31
JP2020203889A (ja) 2020-12-24
CO6361952A2 (es) 2012-01-20
CN114225022A (zh) 2022-03-25
JP2018168158A (ja) 2018-11-01
HK1159130A1 (zh) 2012-07-27
WO2010066762A1 (en) 2010-06-17
CN102245639A (zh) 2011-11-16
IL264316B2 (en) 2024-01-01
KR101762966B1 (ko) 2017-07-31
PT2376533T (pt) 2016-07-13
HUE056626T2 (hu) 2022-02-28
AU2009324371B2 (en) 2013-10-10
JP6143416B2 (ja) 2017-06-07
CL2011001406A1 (es) 2012-03-30
TN2011000229A1 (en) 2012-12-17
CN102245639B (zh) 2014-12-24
CN104399076B (zh) 2021-09-14
PE20120342A1 (es) 2012-04-24
JP2015231997A (ja) 2015-12-24
ES2900624T3 (es) 2022-03-17
JP2026021446A (ja) 2026-02-10
PL2376533T3 (pl) 2016-09-30
EP3072906A1 (en) 2016-09-28
US20120315285A1 (en) 2012-12-13
CA2745938A1 (en) 2010-06-17
EP3792282A1 (en) 2021-03-17
EP3072906B1 (en) 2021-09-08
KR20120009421A (ko) 2012-01-31
US20110236398A1 (en) 2011-09-29
MA33023B1 (fr) 2012-02-01
AU2009324371A1 (en) 2011-06-23
CA2745938C (en) 2018-04-24
KR20170044211A (ko) 2017-04-24
ES2579835T3 (es) 2016-08-17
CY1124844T1 (el) 2022-11-25

Similar Documents

Publication Publication Date Title
US20200384108A1 (en) Liquid il-1 beta antibody formulation having ph of 5.5 to 7.0
EP1409018B1 (en) Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
JP2020063261A (ja) ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤
US9833410B2 (en) Lyophilized formulation comprising GM-CSF neutralizing compound
AU2015257798A1 (en) Liquid formulation comprising GM-CSF neutralizing compound
PH12015500864B1 (en) Liquid formulation comprising gm-csf neutralizing compound
HK40041917A (en) Antibody formulation
HK1159130B (en) Antibody formulation
Kluge et al. Tumor necrosis factor-neutralization with a specific monoclonal antibody
HK1235316A1 (en) Liquid formulation comprising gm-csf neutralizing compound

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]